NCT05011279

Move Together Boston Feasibility Pilot (Sit Less, Move More App for Black Breast Cancer Survivors & At-Risk Relatives)

Completed NA Results posted Last updated 15 November 2023

What this trial tests

NA trial testing Move Together app/Garmin Activity Tracker in Breast Cancer Survivor in 10 participants. Completed in 21 January 2022.

Timeline

10 September 2021

Primary endpoint
21 January 2022

21 January 2022

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	10
Start date	10 September 2021
Primary completion	21 January 2022
Estimated completion	21 January 2022
Sites	3 locations across United States

Drugs / interventions tested

• Move Together app/Garmin Activity Tracker

Conditions studied

• Breast Cancer Survivor — all drugs for Breast Cancer Survivor →
• Breast Cancer — all drugs for Breast Cancer →
• Fitness Trackers — all drugs for Fitness Trackers →

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, any sex, with Breast Cancer Survivor or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

System Usability Scale (SUS) Score Primary · Assessed at 4 Weeks

The acceptability of the Move Together app will also be assessed with The System Usability Scale (SUS) score. The scale has 10 items. Scores range from 0-100; a SUS score above a 68 is considered above average (https://www.usability.gov/how-to-and-tools/methods/system-usability-scale.html.)

Group	Value	95% CI
Pilot Study	72	± 14.3

Number of Participants Screened Per Month Secondary · 4 month recruitment period

the number of participants screened per month during recruitment period (not cumulative)

Group	Value	95% CI
Pilot Study	5

Number of Participants Enrolled Per Month Secondary · 4 month enrollment period

number of participants consented to the study each month during enrollment period

Group	Value	95% CI
Pilot Study	3

Completion Rate Secondary · 4 Weeks

number of participants who completed all aspects of the protocol

Group	Value	95% CI
Pilot Study	10

Number of Study Days Secondary · baseline to 4 weeks (28 days)

number of study days in which the participants uses the Move Together app and will describe engagement with the app in a 28 day period (i.e., study days)

Group	Value	95% CI
Pilot Study	17.1	± 8.6

Number of Participants Recruited Secondary · during 4 month recruitment period

Number of initial respondents who consent and enroll.

Group	Value	95% CI
Pilot Study	1

Number of Participants Completed Study Secondary · 4 weeks

Total number of participants who completed the study

Group	Value	95% CI
Pilot Study	9

Number of Participants Retained at the End of 4 Weeks Secondary · Baseline to 4 Weeks

Retention will be the number who remain in the study at the end of 4 weeks

Group	Value	95% CI
Pilot Study	10

Sponsor's own description

The purpose of this study is to develop and test a mobile app for Black/African American breast cancer survivors and their relatives, called Move Together, that promotes sitting less and moving more for better health.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Designing a Dyad-Based Digital Health Intervention to Reduce Sedentary Time in Black Breast Cancer Survivors and Their First-degree Relatives: Human-Centered Design Study.
   Blazey M, Marinac C, Whiteley J, Peterson S, et al · · 2023 · cited 2× · PMID 37223968 · DOI 10.2196/43592